Highlights NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Market Closed - Toronto S.E. Other stock markets 01:29:58 29/06/2024 am IST			5-day change	1st Jan Change
2.69 ^CAD	-1.82%		+16.96%	-0.37%

26/06	Nervgen Pharma Initiated at Market Perform, $3 Price Target at Raymond James	MT
25/06	NervGen Pharma to Advance New Drug Candidate into Preclinical Proof-of-Concept Stage	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NervGen Pharma to Advance New Drug Candidate into Preclinical Proof-of-Concept Stage	25/06	MT
NervGen Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	17/04	MT
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
NervGen Pharma Closes C$23 Million Bought Deal Financing	28/03	MT
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units	22/03	MT
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291	15/02	CI
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23/23/23	CI
NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	25/23/25	CI
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Nervgen Pharma Corp. Receives Institutional Review Board Approval for Its Phase 1B/2A Proof-Of-Concept Clinical Trial Protocol of Its Proprietary Lead Compound, Nvg-291, in Individuals with Spinal Cord Injury	08/23/08	CI
NervGen Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer	10/23/10	MT
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291	14/23/14	CI
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291	25/22/25	CI
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/22/10	CI
NervGen Up 3.5% As Secures TSX-V Approval for US$15.2 Million Non-brokered Private Placement	11/22/11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Highlights

Filters